ADC Biotechnology
We are 100% focused on ADC’s and developing new process technology. To speed, simplify and significantly lower the production costs of the latest generation of anticancer blockbuster ADC drugs. ADC BIO’s proprietary Lock-Release technology is a fast, simple, cost efficient and robust system to guarantee ADCs of a consistently high quality and purity. A bold statement that ADC BIO is expertly equipped and proud to make – and stand by. We’re not fazed by any ADC challenge, just excited by the prospect and process of bringing it to life. The Downing FOUR VCT PLC Healthcare Technology Fund is managed by Downing LLP
Total raised: $1.496428M

Investors 2

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
--$1.496428MDowning Ve...-

Mentions in press and media 2

25.09.2017ADC Biotec...ADC Biotechnology Limited, a
-Downing FO...London-based investment